Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an ...

PITTSBURGH — Some 264,000 women will get a breast cancer diagnosis this year, with 50% to 60% of them having a type of cancer called HER2 low. That means the tumors have low levels of the HER2 ...

Enhertu is already approved for more advanced cases of HER2-positive breast cancer, as well as a string of other oncology indications, and made $3.75 billion in sales last year while adding ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A mum from Banbury with breast cancer said a life-extending drug would be 'worth it', as a charity speaks out on the 'unfair' ...

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with major updates for antibody-drug conjugates, HER2-positive regimens, and ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.